A study to compare immune response of V503 to Gardasil in 16- to 26-year-old men

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-003399-10

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to demonstrate that administration of the 9vHPVvaccine induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL® in 16- to 26-year-old men.


Critère d'inclusion

  • Prevention of premalignant genital lesions (cervical, vulvar and vaginal) and cervical cancer and genital warts (condyloma acuminata) causally related to Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58